HONG KONG SAR – Leveraging Clinical Science <\/b>to Create a Commercial Advantage through Consumer Health<\/b>\n<\/p>\n The Nugevia product line is founded on Jupiter’s patented JOTROL\u2122 resveratrol delivery platform which demonstrated a nine-fold increase in bioavailability in Phase I clinical trials. By capitalizing on this clinical data, Jupiter is introducing pharmaceutical-grade science to the longevity marketplace. The Company is strategically executing a dual-path business model that simultaneously advances its CNS therapeutic programs while capturing value in the $8 trillion and rapidly growing global longevity and wellness market.\n<\/p>\n \n“The launch of Nugevia\u2122 represents a pivotal inflection point for Jupiter Neurosciences,” said Christer Ros\u00e9n, Chairman and CEO of Jupiter Neurosciences. “We are leveraging the culmination of decades of CNS research and our clinically validated JOTROL\u2122 technology to establish a new, capital-efficient growth engine by giving consumers access to clinically validated wellness products. Launching the Nugevia website and enabling pre-orders is a significant milestone we have looked forward to for several years, and investors should view this as a powerful step forward in our strategy to build a diversified and sustainable business that complements and supports the research and development of our pharmaceutical pipeline.”<\/p>\n A Capital-Efficient Growth Strategy<\/b>\n<\/p>\n The Nugevia launch serves as the foundation of a new commercial channel that directly complements the Company’s clinical development programs. By building a premium consumer longevity product line rooted in clinical science, the Company is creating a near-term revenue stream that supports ongoing R&D and enhances financial flexibility.\n<\/p>\n Introducing Nugevia\u2122 Brand Ambassadors <\/b>\n<\/p>\n Hall of Fame golfer Annika S\u00f6renstam and NBA legend Chris Webber have been named as our first two Nugevia\u2122<\/b> brand ambassadors. Both bring global visibility and credibility, reinforcing our brand alignment with high performance, healthy aging, and scientific innovation.\n<\/p>\n Availability<\/b>\n<\/p>\n Pre-orders for Nugevia\u2122 GLO, PWR, and MND are now available at Hashtag: <\/b>#JupiterNeurosciences #JUNS #Nugevia #JOTROL #LongevityMarket #NeuroHealth #HealthyAging <\/p>\n
\nMedia OutReach Newswire<\/a> – 27 August 2025 – Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company pioneering therapies for central nervous system (CNS) disorders and advancing science-based consumer health solutions, today announced a pivotal expansion of its dual-path business model with the launch of its dedicated Nugevia\u2122 e-commerce website,
\nwww.nugevia.com<\/a>, and the opening of pre-orders for its first three nutraceutical supplements: Nugevia\u2122 GLO, Nugevia\u2122 PWR, and Nugevia\u2122 MND. The products are available for purchase via subscription or as a one-time order, with shipping scheduled to begin this Fall.<\/p>\n\n
\nwww.nugevia.com<\/a>. Consumers can choose flexible subscription options or one-time purchases, with product delivery starting in Fall 2025.\n<\/p>\n![](\"https:\/\/release.media-outreach.com\/Release\/templates\/images\/socialMedia\/generic_link.png\")
https:\/\/jupiterneurosciences.com\/<\/a>![](\"https:\/\/release.media-outreach.com\/Release\/templates\/images\/socialMedia\/iconmonstr-linkedin-1-24.png\")
https:\/\/www.linkedin.com\/company\/jupiterneurosciences\/<\/a>![](\"https:\/\/release.media-outreach.com\/Release\/templates\/images\/socialMedia\/iconmonstr-twitter-1-24.png\")
https:\/\/x.com\/jupiterneuro<\/a> <\/p>\n